3 unchanged lines
Hypoxia [see Warnings and Precautions (5.2)]
Cardiac Dysfunction with Concomitant Use of WELIREG and Lenvatinib [see Warnings and Precautions (5.3)]
6.1 Clinical Trials Experience
8 unchanged lines
The most common (≥25%) adverse reactions, including laboratory abnormalities, that occurred in patients who received WELIREG were decreased hemoglobin, fatigue, increased creatinine, headache, dizziness, increased glucose, and nausea.
Table 34 summarizes the adverse reactions reported in patients treated with WELIREG in LITESPARK-004.
Table 34: Adverse Reactions Occurring in ≥10% of Patients Who Received WELIREG in LITESPARK-004
Adverse Reaction | WELIREG (n=61)
22 unchanged lines
Weight increased | 12 | 1.6
Table 45 summarizes the laboratory abnormalities in LITESPARK-004.
Table 45: Select Laboratory Abnormalities (≥10%) That Worsened from Baseline in Patients Who Received WELIREG in LITESPARK-004
Laboratory Abnormality | WELIREG (n=61)
12 unchanged lines
LITESPARK-022
The safety of WELIREG in combination with intravenous pembrolizumab versus placebo in combination with intravenous pembrolizumab was investigated in LITESPARK-022, a randomized, double-blind trial in 1,828 patients who had undergone nephrectomy for ccRCC [see Clinical Studies (14.2)]. Patients received either WELIREG 120 mg orally once daily in combination with pembrolizumab 400 mg intravenously every 6 weeks (n=915), or oral placebo in combination with pembrolizumab 400 mg intravenously every 6 weeks (n=913) for up to 9 cycles (54 weeks) until disease recurrence or unacceptable toxicity. The median duration of exposure to WELIREG was 12.4 months (range: 1 day to 20.1 months).
Serious adverse reactions occurred in 30% of patients who received WELIREG in combination with pembrolizumab. Serious adverse reactions in ≥1% of patients included pneumonia (2%), hypoxia (1.9%), pneumonitis (1.6%), arrhythmia (1.5%), diarrhea (1.1%), and acute kidney injury (1.1%). Fatal adverse reactions occurred in 1.1% of patients who received WELIREG in combination with pembrolizumab, including sepsis (0.1%).
3 unchanged lines
The most common (≥25%) adverse reactions, including laboratory abnormalities, in patients who received WELIREG in combination with pembrolizumab were decreased hemoglobin, increased ALT, fatigue, increased AST, decreased lymphocytes, and increased alkaline phosphatase.
Tables 56 and 67 summarize the adverse reactions and laboratory abnormalities, respectively, in LITESPARK-022.
Table 56: Adverse Reactions (≥10%) in Patients with ccRCC Who Received WELIREG in Combination with Pembrolizumab [at a Higher Incidence (Between Arm Difference of ≥4%) Compared to Control] in LITESPARK-022
Adverse Reaction | WELIREG plus Pembrolizumab (n=915) | Placebo plus Pembrolizumab (n=913)
11 unchanged lines
Clinically relevant adverse reactions in <10% of patients who received WELIREG in combination with pembrolizumab included hypertension (7%), hypoxia (7%), visual impairment (6.1%), arrhythmia (5%), hemorrhage (4.6%), chest discomfort (2.6%), and palpitations (1.9%).
Table 67: Select Laboratory Abnormalities (>≥20%) That Worsened from Baseline In Patients with ccRCC Who Received WELIREG in Combination With Pembrolizumab [at a Higher Incidence (Between Arm Difference of >≥10%) Compared to Control] in LITESPARK-022
Laboratory Test | WELIREG plus Pembrolizumab | Placebo plus Pembrolizumab
7 unchanged lines
Increased alkaline phosphatase | 29 | 2.3 | 18 | 0.4
LITESPARK-011
The safety of WELIREG in combination with lenvatinib was evaluated in patients with advanced ccRCC that progressed on or after receiving a PD-1 or PD-L1 inhibitor in LITESPARK-011 [see Clinical Studies (14.2)]. Patients received WELIREG 120 mg in combination with lenvatinib 20 mg (n=370), or cabozantinib 60 mg (n=371) orally once daily until disease progression or unacceptable toxicity.
The median duration of exposure to WELIREG was 15.8 months (range: 1 day to 50.6 months).
Serious adverse reactions occurred in 54% of patients who received WELIREG in combination with lenvatinib. Serious adverse reactions in ≥2% of patients included hypoxia (6%), pneumonia (5%), hyponatremia (3.2%), acute kidney injury (3%), hemorrhage (2.7%), anemia (2.7%), cardiac failure (2.4%), and diarrhea (2.4%).
Fatal adverse reactions occurred in 5% of patients who received WELIREG in combination with lenvatinib, including sepsis (0.8%), pneumonia (0.5%), pneumonitis (0.5%), respiratory failure (0.5%), and one case (0.3%) each of acute cholecystitis, acute respiratory distress syndrome, pulmonary edema, embolic cerebral infarction, hemorrhage, postoperative wound complication, thrombotic microangiopathy and upper respiratory tract infection.
Permanent discontinuation of WELIREG due to an adverse reaction occurred in 17% of patients. Adverse reactions which resulted in permanent discontinuation of WELIREG in >0.5% of patients included hypoxia (2.2%), pneumonia (1.1%), fatigue (0.8%), hyponatremia (0.8%), pneumonitis (0.8%), and respiratory failure (0.8%).
Dosage interruptions of WELIREG due to an adverse reaction occurred in 69% of patients. Adverse reactions which required dosage interruption in >3% of patients included fatigue (14%), diarrhea (12%), anemia (9%), vomiting (9%), hypertension (9%), nausea (8%), decreased appetite (5%), abdominal pain (4.6%), COVID-19 (4.6%), musculoskeletal pain (4.1%), pneumonia (3.5%), hypoxia (3.5%), and hemorrhage (3.5%).
Dose reductions of WELIREG due to an adverse reaction occurred in 35% of patients. Adverse reactions which required dose reductions in >2% of patients included fatigue (7%), hypoxia (7%), anemia (6%), diarrhea (3%), and dyspnea (2.4%).
The most common (≥25%) adverse reactions, including laboratory abnormalities, that occurred in patients who received WELIREG in combination with lenvatinib were decreased hemoglobin, fatigue, increased AST, hypertension, increased ALT, musculoskeletal pain, diarrhea, decreased lymphocytes, decreased sodium, increased creatinine, nausea, hypothyroidism, decreased appetite, decreased platelets, increased potassium, increased lipase, proteinuria, decreased magnesium, decreased calcium, increased activated partial thromboplastin time, rash, vomiting, decreased weight, constipation, abdominal pain, and stomatitis.
Tables 8 and 9 summarize the adverse reactions and laboratory abnormalities, respectively, in LITESPARK-011.
Table 8: Adverse Reactions (≥15%) in Patients with Advanced ccRCC Who Received WELIREG in Combination with Lenvatinib in LITESPARK-011
Adverse Reaction | WELIREG plus Lenvatinib (n=370) | Cabozantinib (n=371)
All Grades (%) | Grade 3-4 (%) | All Grades (%) | Grade 3-4 (%)
General
Fatigue | 68 | 16 | 60 | 9
Edema | 17 | 0.3 | 10 | 0.3
Vascular
Hypertension | 60 | 33 | 58 | 30
Hemorrhage | 20 | 3 | 16 | 3
Musculoskeletal and connective tissue
Musculoskeletal pain | 55 | 5 | 43 | 4
Gastrointestinal
Diarrhea | 54 | 8 | 71 | 11
Nausea | 42 | 3.8 | 39 | 1.1
Vomiting | 32 | 0.8 | 17 | 1.1
Constipation | 27 | 0.8 | 23 | 0
Abdominal pain | 26 | 1.6 | 27 | 1.9
Stomatitis | 25 | 1.9 | 46 | 5
Endocrine
Hypothyroidism | 42 | 0.3 | 37 | 0
Metabolism and nutrition
Decreased appetite | 41 | 2.7 | 40 | 3.5
Renal and urinary
Proteinuria | 38 | 10 | 20 | 3.5
Skin and subcutaneous tissue
Rash | 33 | 2.7 | 61 | 10
Investigations
Weight decreased | 29 | 5 | 30 | 6
Nervous system
Headache | 24 | 0.5 | 13 | 0
Dizziness | 16 | 0.8 | 11 | 0.3
Respiratory, Thoracic and Mediastinal
Cough | 19 | 0 | 18 | 0.5
Dyspnea | 17 | 1.9 | 11 | 1.1
Hypoxia | 16 | 12 | 0 | 0
Clinically relevant adverse reactions occurring in <15% of patients who received WELIREG in combination with lenvatinib included COVID-19 (14%), dysphonia (14%), dysgeusia (14%), urinary tract infection (14%), pruritus (12%), pyrexia (11%), and arrhythmia (9%).
Table 9: Select Laboratory Abnormalities (≥20%) That Worsened from Baseline In Patients with Advanced ccRCC Who Received WELIREG in Combination with Lenvatinib in LITESPARK-011
Laboratory Test | WELIREG plus Lenvatinib | Cabozantinib
All Grades % | Grades 3-4 % | All Grades % | Grades 3-4 %
Hematology
Decreased hemoglobin | 87 | 17 | 50 | 7
Decreased lymphocytes | 53 | 15 | 45 | 18
Decreased platelets | 40 | 1.9 | 43 | 0.3
Increased activated partial thromboplastin time | 34 | 2.5 | 27 | 2.5
Decreased neutrophils | 21 | 4.9 | 29 | 3.8
Chemistry
Increased AST | 65 | 7 | 84 | 6
Increased ALT | 56 | 7 | 77 | 7
Decreased sodium | 47 | 7 | 49 | 4.6
Increased creatinine | 42 | 3.8 | 36 | 2.4
Increased potassium | 39 | 5 | 38 | 6
Increased lipase | 38 | 15 | 50 | 17
Decreased magnesium | 37 | 1.4 | 51 | 4.7
Decreased calcium | 35 | 2.4 | 62 | 3.5
Decreased potassium | 23 | 3.5 | 26 | 5
Increased calcium | 20 | 0.3 | 11 | 0.5
LITESPARK-005
The safety of WELIREG was evaluated in a randomized, active-controlled study (LITESPARK- 005) in 732 patients with advanced ccRCC that has progressed after prior PD-1 or PD-L1 checkpoint inhibitor and VEGF receptor targeted therapies [see Clinical Studies (14.2)]. Patients received 120 mg WELIREG (n=372) or 10 mg everolimus (n=360) orally once daily until disease progression or unacceptable toxicity. The median duration of exposure to WELIREG was 7.6 months (range: 0.1 to 28.5 months).
Serious adverse reactions occurred in 38% of patients who received WELIREG. Serious adverse reactions in ≥2% of patients treated with WELIREG were hypoxia (7%), anemia (5%), pneumonia (3.5%), hemorrhage (3%), and pleural effusion (2.2%). Fatal adverse reactions occurred in 3.2% of patients who received WELIREG, including sepsis (0.5%) and hemorrhage (0.5%).
3 unchanged lines
The most common (≥25%) adverse reactions, including laboratory abnormalities, that occurred in patients who received WELIREG were decreased hemoglobin, fatigue, musculoskeletal pain, increased creatinine, decreased lymphocytes, increased alanine aminotransferase, decreased sodium, increased potassium, and increased aspartate aminotransferase.
Table 710 summarizes the adverse reactions in LITESPARK-005.
Table 710: Adverse Reactions (≥10%) in Patients with Advanced RCC Receiving WELIREG in LITESPARK-005
Adverse Reaction | WELIREG (n=372) | Everolimus (n=360)
16 unchanged lines
Decreased Appetite | 13 | 1.1 | 16 | 0
Nervous Systems
Nervous System
Headache | 12 | 0.5 | 8 | 0.3
1 unchanged line
Clinically relevant adverse reactions in <10% of patients who received WELIREG in LITESPARK-005 included hemorrhage (9%) [including intracranial/cerebral hemorrhage (0.8%)], rash (8%), hypertension (6%), visual impairment [including vision blurred (4%), visual acuity decreased (1.1%), visual impairment (0.5%), and retinal detachment (0.3%)] (6%) and increased weight (5%).
Table 811 summarizes the laboratory abnormalities in LITESPARK-005.
Table 811: Select Laboratory Abnormalities (≥20%) That Worsened from Baseline In Patients with Advanced RCC who Received WELIREG in LITESPARK-005
Laboratory Test | WELIREG | Everolimus
20 unchanged lines
The most common (≥25%) adverse reactions, including laboratory abnormalities, that occurred in patients who received WELIREG were anemia, fatigue, musculoskeletal pain, decreased lymphocytes, increased alanine aminotransferase, increased aspartate aminotransferase, increased calcium, dyspnea, increased potassium, decreased leukocytes, headache, increased alkaline phosphatase, dizziness, and nausea.
Table 912 summarizes the adverse reactions reported in patients treated with WELIREG in LITESPARK-015.
Table 912: Adverse Reactions Occurring in ≥10% of Patients with PPGL Who Received WELIREG in LITESPARK-015
Adverse Reaction | WELIREG (n=72)
37 unchanged lines
Palpitations | 10 | 0
Table 1013 summarizes the laboratory abnormalities in LITESPARK-015.
Table 1013: Select Laboratory Abnormalities (≥20%) That Worsened from Baseline in Patients with PPGL Who Received WELIREG in LITESPARK-015
Laboratory Abnormality | WELIREG (n=72)
15 unchanged lines